227 related articles for article (PubMed ID: 27241955)
41. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
Richert T; Johnson B
Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
[TBL] [Abstract][Full Text] [Related]
42. Cause-specific mortality among people previously hospitalized with opioid-related conditions: a retrospective cohort study.
Veldhuizen S; Callaghan RC
Ann Epidemiol; 2014 Aug; 24(8):620-4. PubMed ID: 25084705
[TBL] [Abstract][Full Text] [Related]
43. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.
Pierce M; Bird SM; Hickman M; Marsden J; Dunn G; Jones A; Millar T
Addiction; 2016 Feb; 111(2):298-308. PubMed ID: 26452239
[TBL] [Abstract][Full Text] [Related]
44. Mortality among opiate users: opioid maintenance therapy, age and causes of death.
Clausen T; Waal H; Thoresen M; Gossop M
Addiction; 2009 Aug; 104(8):1356-62. PubMed ID: 19426288
[TBL] [Abstract][Full Text] [Related]
45. An estimation of the prevalence of opioid dependence in New Zealand.
Adamson SJ; Deering DE; Sellman JD; Sheridan J; Henderson C; Robertson R; Pooley S; Campbell SD; Frampton CM
Int J Drug Policy; 2012 Jan; 23(1):87-9. PubMed ID: 21696937
[TBL] [Abstract][Full Text] [Related]
46. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.
Bruneau J; Roy E; Arruda N; Zang G; Jutras-Aswad D
Addiction; 2012 Jul; 107(7):1318-27. PubMed ID: 22248184
[TBL] [Abstract][Full Text] [Related]
47. Retention in Georgia opioid substitution therapy program and associated factors.
Ruadze E; Todadze K
Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
[TBL] [Abstract][Full Text] [Related]
48. Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013.
Ledberg A
J Subst Abuse Treat; 2017 Mar; 74():35-41. PubMed ID: 28132698
[TBL] [Abstract][Full Text] [Related]
49. Cessation of groin injecting behaviour among patients on oral opioid substitution treatment.
Senbanjo R; Hunt N; Strang J
Addiction; 2011 Feb; 106(2):376-82. PubMed ID: 20955492
[TBL] [Abstract][Full Text] [Related]
50. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis.
Kimmel SD; Walley AY; Li Y; Linas BP; Lodi S; Bernson D; Weiss RD; Samet JH; Larochelle MR
JAMA Netw Open; 2020 Oct; 3(10):e2016228. PubMed ID: 33052402
[TBL] [Abstract][Full Text] [Related]
51. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study.
Cousins G; Boland F; Courtney B; Barry J; Lyons S; Fahey T
Addiction; 2016 Jan; 111(1):73-82. PubMed ID: 26234389
[TBL] [Abstract][Full Text] [Related]
52. Retention of service users on opioid substitution therapy in the City of Tshwane, South Africa.
Goeieman DS; Nonyane DS; Nzaumvila DK; Anse van Rensburg MNS
Afr J Prim Health Care Fam Med; 2023 Jan; 15(1):e1-e10. PubMed ID: 36744456
[TBL] [Abstract][Full Text] [Related]
53. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
Bird SM; Goldberg DJ; Hutchinson SJ
J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
[TBL] [Abstract][Full Text] [Related]
54. Long-term mortality and causes of death among hospitalized Swedish drug users.
Fugelstad A; Annell A; Ågren G
Scand J Public Health; 2014 Jun; 42(4):364-9. PubMed ID: 24608092
[TBL] [Abstract][Full Text] [Related]
55. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
[TBL] [Abstract][Full Text] [Related]
56. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.
Degenhardt L; Bucello C; Mathers B; Briegleb C; Ali H; Hickman M; McLaren J
Addiction; 2011 Jan; 106(1):32-51. PubMed ID: 21054613
[TBL] [Abstract][Full Text] [Related]
57. Changes in opioid-related deaths following increased access to opioid substitution treatment.
Andersson L; Håkansson A; Berge J; Johnson B
Subst Abuse Treat Prev Policy; 2021 Feb; 16(1):15. PubMed ID: 33568184
[TBL] [Abstract][Full Text] [Related]
58. The risk of cancer among persons with a history of injecting drug use in Sweden - a cohort study based on participants in a needle exchange program.
Reepalu A; Blomé MA; Björk J; Widell A; Björkman P
Acta Oncol; 2012 Jan; 51(1):51-6. PubMed ID: 22150166
[TBL] [Abstract][Full Text] [Related]
59. 'Not just methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings.
Rance J; Treloar C;
Addiction; 2014 Mar; 109(3):452-9. PubMed ID: 24678545
[TBL] [Abstract][Full Text] [Related]
60. Examining non-AIDS mortality among people who inject drugs.
Mathers BM; Degenhardt L
AIDS; 2014 Nov; 28 Suppl 4(4):S435-44. PubMed ID: 25409098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
